Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03838042
Title INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University Hospital Heidelberg
Indications

brain ependymoma

rhabdoid cancer

nephroblastoma

bone sarcoma

high grade glioma

embryonal rhabdomyosarcoma

neuroblastoma

atypical teratoid rhabdoid tumor

alveolar rhabdomyosarcoma

medulloblastoma

Therapies

Entinostat + Nivolumab

Age Groups: adult | senior
Covered Countries FRA | DEU | AUT


No variant requirements are available.